Diagnostics
Epigenomics AG announced its financial results for the first nine months of 2019.
Ellume Limited is pleased to announce the appointment of Ms Joanne Moss to its Board as an Independent Non-Executive Director and Chair of Audit and Risk, effective immediately.
Roche intends to hold two global meetings with members of the DMD community to provide the stakeholders with as much information as possible.
Both Owlstone and Thermo Fisher will work together to integrate Thermo Fisher’s Orbitrap gas chromatography mass spectrometry instrumentation into Owlstone Medical’s Breath Biopsy platform.
BillionToOne and Eluthia have announced the launch of the first and only non-invasive prenatal test, allowing to screen for the autosomal-recessive conditions cystic fibrosis, spinal muscular atrophy, sickle cell disease and other hemoglobinopathies.
Large-scale public-private research initiative designed to provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases
Financing will support Sense’s development of instrument-free molecular diagnostics aimed at true point-of-care testing
Sense Biodetection Limited raises £12.3m to progress instrument-free molecular diagnostics
Initial focus on diagnosing infectious disease through development of machine-free, lab-quality, True Point-of-Care™ products
Edan Diagnostics, Inc., a wholly own subsidiary of Edan Instruments, Inc., a world leader in the development and manufacture of bio-electronic devices and laboratory analyzers for medical diagnostics, and LGC, a global life science tools leader, announced today the sale of LGC’s ClariLight molecular diagnostics POC platform to Edan.
PRESS RELEASES